1. Medtech Insight
  2. >>Policy & Regulation

Device-Related Procedure Costs To Be Revealed Under CMS Proposed Payment Rule

 
• By Sue Darcey

US hospitals would have to reveal on a public website their standard charges and insurer-negotiated prices for a long list of device-related procedures, advanced imaging scans, and lab tests under a proposed Centers for Medicare and Medicaid Services rule released on 29 July.

Male doctor or practitioner using calculator and work on laptop computer with medical stethoscope on the desk at clinic or hospital. Medical healthcare costs ,fees and revenue concept. - Image

Every hospital in the US would have to publicize and post its charges and negotiated prices for common hospital procedures – including device-related ones – and advanced imaging scans, laboratory tests, and supplies, says a new proposed rule from the Centers for Medicare and Medicaid Services (CMS).

The Increasing Price Transparency proposed rule, part of the CMS 2020 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By Ashley Yeo

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Deals Shaping The Medtech And Diagnostics Industries, July 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.